Effects of S-Adenosyl Methionine (SAMe) on Viral and Cell Signaling Response to Combination Therapy for Chronic Hepatitis C.

Trial Profile

Effects of S-Adenosyl Methionine (SAMe) on Viral and Cell Signaling Response to Combination Therapy for Chronic Hepatitis C.

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Jul 2013

At a glance

  • Drugs Ademetionine (Primary) ; Peginterferon alfa-2a; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 May 2011 Actual end date (May 2011) added as reported by ClinicalTrials.gov
    • 17 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 13 Apr 2010 Planned end date changed from 1 Feb 2009 to 1 Feb 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top